Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 3/2008

01.06.2008 | Research Article

Cost of illness of tuberculosis in Penang, Malaysia

verfasst von: Elfatih Ibrahim Elamin, Mohamed Izham Mohamed Ibrahim, Syed Azhar Syed Sulaiman, Abdul Razak Muttalif

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

Objective To assess the costs incurred by the public health services and patients as a result of tuberculosis (TB) treatment. Setting The study was conducted in a government hospital located in the northern region of Malaysia. Method Retrospective data were collected from medical records and the patients were observed until the completion of their medication. A pharmacoeconomic evaluation was applied to calculate direct and indirect costs. Main Outcome Measure Direct and indirect costs of tuberculosis treatment in a government health institution. Results Two hundred and one tuberculosis patients were included in the study. Different regimens with various durations of treatments were used. The direct medical and non-medical costs as well as indirect costs were calculated and were found to be as follows: US$61.44 for anti-tuberculosis drugs and supplies, US$28.63 for X-ray examinations, US$28.53 for laboratory tests, US$20.03 for healthcare staff time, US$4.28 for hospitalisation, US$43.20 for overhead costs, US$608.11 for transportation and meals and US$118.78 for time away from work. The cost to the patients constitutes approximately 80% of the total cost of the treatment. Conclusion The cost of treating the illness of tuberculosis per patient was US$916.4. The cost of anti-tuberculosis drugs constituted the highest proportion of the cost to the public health services (31.7%) while the cost to the patient constituted the major proportion of the total cost of the illness (79.4%).
Literatur
1.
Zurück zum Zitat World Health Organization. Anti-tuberculosis drug resistance in the world. Geneva: WHO Global TB Programme; 1997. World Health Organization. Anti-tuberculosis drug resistance in the world. Geneva: WHO Global TB Programme; 1997.
2.
Zurück zum Zitat Elsony A, Suliaman E, Shinawy A. Manual of tuberculosis control programme in Sudan, 3rd ed. Sudan: Federal Ministry of Health; 2000. Elsony A, Suliaman E, Shinawy A. Manual of tuberculosis control programme in Sudan, 3rd ed. Sudan: Federal Ministry of Health; 2000.
3.
Zurück zum Zitat American Thoracic Society. Diagnostic standard, classification of TB in adults and children. Am. J. Respir. Care Med. 2000;161:1376–95. American Thoracic Society. Diagnostic standard, classification of TB in adults and children. Am. J. Respir. Care Med. 2000;161:1376–95.
4.
Zurück zum Zitat World Health Organization. Towards a TB free future. Geneva: WHO/CDS/STB; 2001. World Health Organization. Towards a TB free future. Geneva: WHO/CDS/STB; 2001.
5.
Zurück zum Zitat The Caribbean Epidemiology Centre. Tuberculosis manual of prevention & control procedures 1st ed. Trinidad; 1997. The Caribbean Epidemiology Centre. Tuberculosis manual of prevention & control procedures 1st ed. Trinidad; 1997.
6.
Zurück zum Zitat World Health Organization. The economic impacts of tuberculosis. Amsterdam: Stop TB Initiative; 2000. World Health Organization. The economic impacts of tuberculosis. Amsterdam: Stop TB Initiative; 2000.
7.
Zurück zum Zitat Wyss K, Kilima P, Lorenz N. Cost of tuberculosis for household and health care providers in Dar es Salaam, Tanzania. Trop. Med. Int. Health 2001;6:60–8.PubMedCrossRef Wyss K, Kilima P, Lorenz N. Cost of tuberculosis for household and health care providers in Dar es Salaam, Tanzania. Trop. Med. Int. Health 2001;6:60–8.PubMedCrossRef
8.
Zurück zum Zitat Iseman M, Chan E. Current medical treatment for tuberculosis. BMJ 2002;320:282–6. Iseman M, Chan E. Current medical treatment for tuberculosis. BMJ 2002;320:282–6.
9.
Zurück zum Zitat Lyawoo K. Tuberculosis in Malaysia: problems and prospect of treatment and control. Tuberculosis 2004;84:4–7.CrossRef Lyawoo K. Tuberculosis in Malaysia: problems and prospect of treatment and control. Tuberculosis 2004;84:4–7.CrossRef
10.
Zurück zum Zitat Malaysia Tuberculosis Control Programme. NTB report for the year 2001. Malaysia: Ministry of Health; 2001. Malaysia Tuberculosis Control Programme. NTB report for the year 2001. Malaysia: Ministry of Health; 2001.
11.
Zurück zum Zitat Zwarenstein M, Schoeman J, Vundule C, Lombard C, Tatley M. Randomised controlled trial of self-supervised and directly observed treatment of Tuberculosis. Lancet 1998;352:1340–1343.PubMedCrossRef Zwarenstein M, Schoeman J, Vundule C, Lombard C, Tatley M. Randomised controlled trial of self-supervised and directly observed treatment of Tuberculosis. Lancet 1998;352:1340–1343.PubMedCrossRef
12.
Zurück zum Zitat Jerant A, Bannon M, Rittenhouse S. Identification and management of Tuberculosis. Am. Fam. Physician 2000;61:2667–2678.PubMed Jerant A, Bannon M, Rittenhouse S. Identification and management of Tuberculosis. Am. Fam. Physician 2000;61:2667–2678.PubMed
13.
Zurück zum Zitat Centers for Disease Control and Prevention. Core curriculum on tuberculosis, 4th ed. Atlanta: Department of Health & Human services; 2000. Centers for Disease Control and Prevention. Core curriculum on tuberculosis, 4th ed. Atlanta: Department of Health & Human services; 2000.
14.
Zurück zum Zitat Islam M, Wakai S, Ishikawa N, Chowdhury A, Vaughan J. Cost-effectiveness of community health workers in tuberculosis control in Bangladesh. Bull. World Health Organ. 2002;80:445–50.PubMed Islam M, Wakai S, Ishikawa N, Chowdhury A, Vaughan J. Cost-effectiveness of community health workers in tuberculosis control in Bangladesh. Bull. World Health Organ. 2002;80:445–50.PubMed
15.
Zurück zum Zitat Sanderson P. An economic evaluation of alternative programme designs for Tuberculosis control in rural Uganda. Soc. Sci. Med. 1995;40:1203–1212.CrossRef Sanderson P. An economic evaluation of alternative programme designs for Tuberculosis control in rural Uganda. Soc. Sci. Med. 1995;40:1203–1212.CrossRef
16.
Zurück zum Zitat Hurtiga A, Pande S, Porter J, Dam D. Tuberculosis treatment and private practitioners in Kathmandu Valley. J. Nap. Med. Assoc. 2000;39:163–8. Hurtiga A, Pande S, Porter J, Dam D. Tuberculosis treatment and private practitioners in Kathmandu Valley. J. Nap. Med. Assoc. 2000;39:163–8.
17.
Zurück zum Zitat Guwatudde D, Zalwango S, Kamy M, Debanne S, Diaz M, Okwera A, Mugerwa R, King C, Whalen C. Burden of tuberculosis in Kamala, Uganda. Bull. World Health Organ. 2003;81(11):799–805.PubMed Guwatudde D, Zalwango S, Kamy M, Debanne S, Diaz M, Okwera A, Mugerwa R, King C, Whalen C. Burden of tuberculosis in Kamala, Uganda. Bull. World Health Organ. 2003;81(11):799–805.PubMed
18.
Zurück zum Zitat Centers for Disease Control and Prevention. morbidity and mortality weekly report–treatment of tuberculosis. June 20, 2003/52(RR11);1–77. Centers for Disease Control and Prevention. morbidity and mortality weekly report–treatment of tuberculosis. June 20, 2003/52(RR11);1–77.
Metadaten
Titel
Cost of illness of tuberculosis in Penang, Malaysia
verfasst von
Elfatih Ibrahim Elamin
Mohamed Izham Mohamed Ibrahim
Syed Azhar Syed Sulaiman
Abdul Razak Muttalif
Publikationsdatum
01.06.2008
Verlag
Springer Netherlands
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 3/2008
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-007-9185-0

Weitere Artikel der Ausgabe 3/2008

International Journal of Clinical Pharmacy 3/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.